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THE PROFILAGGRIN/FILAGGRIN PROTEIN
Mutations in the filaggrin gene (FLG)
are one of the most common patho-
genic single-gene defects identified to
date. FLG encodes an important epi-
dermal protein abundantly expressed in
the outer layers of the epidermis (Sandi-
lands et al., 2009). Approximately 10%
of individuals of European ancestry are
heterozygous carriers of a loss-of-func-
tion mutation in FLG resulting in a 50%
reduction in expressed protein (Irvine
and McLean, 2006).
As a protein, filaggrin is an unusual
beast in biology. It is expressed as a
giant, inactive, polymeric protein, pro-
filaggrin, which is a major constituent
of keratohyalin granules. At the inter-
face between the outermost granular
layer keratinocytes and the stratum
corneum, this proprotein is cleaved
into several identical filaggrin subunits.
It has been postulated that these
monomers condense the cytoskeleton
and contribute to squame formation. In
the cornified layers per se, filaggrin
undergoes further posttranslational
modifications and is ultimately proteo-
lyzed into a hygroscopic pool of amino
acids and chemical derivatives thereof,
termed natural moisturizing factor
(NMF). Thus, filaggrin has a central
role in the biogenesis and subsequent
hydration of the stratum corneum
(Irvine et al., 2011).
DISEASE ASSOCIATIONS
The identification of an association of
filaggrin with atopic dermatitis (AD)
was a slow burning one. Shortly after
the identification of this protein in the
late 1970s (Dale, 1977), its role in
keratin filament aggregation was ra-
pidly established (Dale et al., 1978).
Some 7 years later, the first evidence
that filaggrin was of potential causal
interest in ichthyosis vulgaris (IV)
emerged (Sybert et al., 1985). It was
to take a further two decades to fully
disclose the molecular genetics of IV.
That delay was due, in large part, to the
technical difficulty of sequencing this
highly repetitive gene and also due to
the confusing inheritance of IV, which
it transpired, which was best explained
by semi-dominant Mendelian inheri-
tance, rather than by traditionally
understood dominant or recessive in-
heritance (Smith et al., 2006).
Once Smith et al. (2006) had
cracked the technical aspects of
sequencing FLG in carefully chosen
clinical pedigrees, the first two recur-
rent loss-of-function mutations (R501X
and 2282del4) were identified. Identi-
fication of further recurrent mutations
swiftly followed (Sandilands et al.,
2007). Surprisingly, these mutations
proved to be prevalent in European
populations, with B9% of these
populations carrying at least one FLG
mutation (Irvine et al., 2011). An ethno-
specific mutation profile was seen with
population-specific mutation spectra
reported in well-studied populations
such as the Singapore Chinese (Chen
et al., 2011). In this population, multi-
ple very low-frequency mutations col-
lectively contribute to the overall total,
compared with the Irish population
where five recurrent mutations consti-
tute most of the total mutations (Chen
et al., 2011).
Once the molecular genetics had
been established, rapid genotyping of
large patient collections was possible
and the association with AD was esta-
blished initially in small collections of
Irish children with AD and in Scottish
children with AD and asthma (Palmer
et al., 2006). These findings have since
been replicated many times in varying
disease collections and population
cohorts; the association is one of
the strongest between any gene and
a complex disease (Rodriguez et al.,
2009). Further analysis of additional
disease and population collections
revealed that AD associated with FLG
mutations is, in general, more severe,
more persistent, more ‘atopic’, more
likely to be associated with asthma,
and more likely to have herpes infec-
tions (Irvine et al., 2011). Overall,
collections of AD show a prevalence
of FLG mutations of between 20 and
50% (Irvine, 2007). In addition, FLG
mutations are associated with peanut
allergy (Brown et al., 2011). The totality
of the contribution of filaggrin to hu-
man disease is not limited to low
prevalence loss-of-function mutations,
as more prevalent intragenic copy
number mutations also contribute sub-
stantially to risk, with the total filaggrin
repeat number (the filaggrin index)
significantly predicting AD risk with a
lower odds ratio but a higher frequency
and therefore a significant overall
contribution to disease in addition to
the lower frequency null alleles (Brown
et al., 2012).
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THE ROLE OF FILAGGRIN IN
EPIDERMAL BARRIER FUNCTION
The filaggrin story placed a primary
epidermal barrier defect firmly in the
forefront of AD pathogenesis and has
led to multiple avenues of inquiry to
elucidate early pathogenic pathways
in AD. The flaky tail mouse, a double
mutant for murine Flg and the matted
gene (ma), shows a primary epidermal
barrier defect compounded massively
by allergic inflammation (Fallon et al.,
2009) findings consistent with ex vivo
studies that show evidence for modula-
tion of filaggrin expression by the Th2
cytokines, IL-13 and IL-4 (Howell et al.,
2007). Furthermore, filaggrin may have
pleiotropic effects on multiple path-
ways relevant to the pathogenesis of
AD including on the growth of Staphy-
locccus aureus (Miajlovic et al., 2010),
skin pH (Jungersted et al., 2010), lipid
lamellae secretion and stratum cor-
neum structure (Gruber et al., 2011),
and the expression of pro-inflammatory
cytokines (Kezic et al., 2012). FLG-null
alleles lead directly to decreased stra-
tum corneum NMF (Kezic et al., 2008);
careful assessment of these levels de-
monstrates three separate subpopula-
tions of AD based on FLG genotype,
viz FLGþ /þ , FLGþ /, and FLG/
(O’Regan et al., 2010).
THERAPEUTIC TARGETS
Filaggrin expression is downregulated
in all cases of moderate-to-severe
AD (Kezic et al., 2011), making it an
appropriate therapeutic target for AD
in the broadest sense, rather than
being confined to AD associated with
FLG-null alleles. The filaggrin index
effect, where a modest 20% increase in
filaggrin copy number leads to a 40%
reduction in AD susceptibility (Brown
et al., 2012), is highly suggestive that
filaggrin upregulation therapies will be
of potential wide utility in AD. Com-
paratively little is known about the
regulation of filaggrin gene expression,
although this is now an area of active
interest by academia and pharma alike.
The fact that filaggrin expression has
been shown to be regulated by envir-
onmental humidity (Katagiri et al.,
2003) indicates that there are signaling
pathways in the skin that actively
control filaggrin expression and skin
barrier homeostasis in general. These
are tractable problems that will lead to
specific therapeutic approaches once
these pathways are fully understood
and targeted pharmacologically.
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